SUTRO BIOPHARMA, INC.(STRO)Stock Analysis

STRO Stock Analysis & AI Quality Score

AI stock analysis and institutional research for SUTRO BIOPHARMA, INC. (STRO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores STRO at 30.1/100 on a 32-signal composite quality model, placing it at rank #2,372 of 2,879 stocks — the bottom half of the AI-ranked universe. STRO scores in the top quartile across institutional flow (99.9), revenue growth (90.8). Areas of concern include balance sheet strength (0.6) and free cash flow (5.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 13.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), SUTRO BIOPHARMA, INC. reports quarterly revenue of $14.5M, net income of $-38.5M, free cash flow of $-42.3M. Top institutional holders of STRO by reported 13-F value include BVF /IL, Affinity Asset Advisors,, Samsara BioCapital,, based on the most recent SEC filings. STRO trades on the Nasdaq exchange and files with the SEC under CIK 1382101. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate STRO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for SUTRO BIOPHARMA, INC. directly from SEC EDGAR.